Payment overview · 2025
General Payments
$965.63
59 reported records · 14 companies
Healthcare provider profile · identity verified
Mohammed M. Bakdash, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LUBBOCK, TX · NPI 1629066964
Verified facts
What the public records show
CMS Open Payments records show Mohammed M. Bakdash, M.D. received $965.63 in general payments during 2025 across 59 reported records.
Amgen Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Afrezza by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $266.33 | 27.6% | 28 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $170.73 | 17.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.78 | 12.0% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$95.28 | 9.9% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.49 | 6.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $48.74 | 5.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.25 | 4.1% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $30.92 | 3.2% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $28.88 | 3.0% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $28.58 | 3.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.66 | 2.5% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $17.31 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.14 | 1.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $16.54 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $965.63 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $266.33 | 28 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $170.73 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.78 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $115.78 | 7 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $95.28 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $66.49 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 205 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
205 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 898 | 249 |
| Metformin Hcl Er | Metformin Hcl | 336 | 100 |
| Synthroid | Levothyroxine Sodium | 334 | 88 |
| Glipizide Er | Glipizide | 293 | 87 |
| Mounjaro | Tirzepatide | 205 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 179 | 51 |
| Ozempic | Semaglutide | 117 | 21 |
| Metformin Hcl | Metformin Hcl | 115 | 40 |
| Januvia | Sitagliptin Phosphate | 112 | 29 |
| Tresiba Flextouch U-100 | Insulin Degludec | 111 | 29 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 108 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 105 | 31 |
| Farxiga | Dapagliflozin Propanediol | 105 | 25 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 87 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 25 |
| Ezetimibe | Ezetimibe | 78 | 25 |
| Humalog | Insulin Lispro | 78 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 78 | 16 |
| Repatha Sureclick | Evolocumab | 78 | 16 |
| Vascepa | Icosapent Ethyl | 78 | 19 |
| Jardiance | Empagliflozin | 72 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 22 |
| Lisinopril | Lisinopril | 68 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 20 |
| Glipizide | Glipizide | 63 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 54 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Afrezza | Insulin Regular, Human | 53 | suppressed |
| Methimazole | Methimazole | 51 | 13 |
| Novolog Flexpen | Insulin Aspart | 47 | 19 |
| Trulicity | Dulaglutide | 47 | 12 |
| Glimepiride | Glimepiride | 46 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Novolog | Insulin Aspart | 41 | 17 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 41 | suppressed |
| Simvastatin | Simvastatin | 40 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 39 | 11 |
| Tradjenta | Linagliptin | 39 | 11 |
| Insulin Lispro | Insulin Lispro | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 11 |
| Losartan Potassium | Losartan Potassium | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Np Thyroid | Thyroid,pork | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 23 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Gabapentin | Gabapentin | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $965.63 · 59 records | Amgen Inc. | AFREZZA, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Korlym, MINIMED 780G, MOUNJARO, NP Thyroid 60, REPATHA, Senza, TWIIST, TZIELD, Yorvipath, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error